Funding awarded to develop novel RSV and PIV3 vaccines
Nov 26, 2014
VIDO-InterVac was recently awarded funding from the Canadian Institutes of Health Research to develop vaccines for respiratory syncytial virus and parainfluenza type 3 viruses. This project involves an international team of academia and industry partners including Dalton Pharma Services, the Pan-Provincial Vaccine Enterprise Inc., the South China United Vaccine Institute and the Guangzhou Institute of Respiratory Disease.
Full press release is available at: http://www.dalton.com/news_article_name/novel-vaccines.aspx